{"id":4413,"date":"2019-03-26T03:03:58","date_gmt":"2019-03-26T03:03:58","guid":{"rendered":"https:\/\/www.erdheim-chester.org\/?post_type=study_trials&#038;p=4413"},"modified":"2020-11-03T20:48:56","modified_gmt":"2020-11-03T20:48:56","slug":"dabrafenib-and-trametinib-in-treating-patients-with-erdheim-chester-disease-with-braf-v600-mutations","status":"publish","type":"study_trials","link":"https:\/\/www.erdheim-chester.org\/hi\/study_trials\/dabrafenib-and-trametinib-in-treating-patients-with-erdheim-chester-disease-with-braf-v600-mutations\/","title":{"rendered":"Dabrafenib and Trametinib in Treating Patients With Erdheim Chester Disease With BRAF V600 Mutations"},"content":{"rendered":"<p><strong>\u0905\u0927\u094d\u092f\u092f\u0928 \u0915\u093e \u0909\u0926\u094d\u0926\u0947\u0936\u094d\u092f:&nbsp; <\/strong>This phase II trial investigates the efficacy and safety of dabrafenib and trametinib treatment in patients with Erdheim Chester disease that have BRAF V600 gene mutations.<br \/>\n<strong>\u092a\u094d\u0930\u093e\u092f\u094b\u091c\u0915:<\/strong>&nbsp; National Cancer Institute (NCI)<br \/>\n<strong>\u092a\u0930\u0940\u0915\u094d\u0937\u0923 \u0938\u0902\u092a\u0930\u094d\u0915 \u091c\u093e\u0928\u0915\u093e\u0930\u0940:<\/strong>&nbsp; Study Coordinator: Ms. Abha Adat, aadat@mdanderson.org, or the Principal Investigator Filip Janku, 713-563-1930, FJanku@mdanderson.org.<br \/>\n<strong>\u0905\u0928\u0941\u0930\u094b\u0927\u093f\u0924 \u0930\u094b\u0917\u0940 \u0938\u0939\u092d\u093e\u0917\u093f\u0924\u093e:<\/strong>&nbsp; ECD patients with BRAF V600 mutation who have not previously been treated with a BRAF- or MEK-inhibitor and are 18-years or older.<br \/>\n<strong>\u091f\u094d\u0930\u093e\u092f\u0932 \u092e\u0947\u0902 ECD \u0930\u094b\u0917\u093f\u092f\u094b\u0902 \u0915\u094b \u0938\u094d\u0935\u0940\u0915\u093e\u0930 \u0915\u0930\u0928\u0947 \u0935\u093e\u0932\u0947 \u091c\u094d\u091e\u093e\u0924 \u0915\u0947\u0902\u0926\u094d\u0930:<\/strong>&nbsp; \u090f\u092e\u0921\u0940 \u090f\u0902\u0921\u0930\u0938\u0928, \u0939\u094d\u092f\u0942\u0938\u094d\u091f\u0928, \u091f\u0947\u0915\u094d\u0938\u093e\u0938<br \/>\n<strong>ClinicalTrials.gov \u092a\u0939\u091a\u093e\u0928\u0915\u0930\u094d\u0924\u093e:<\/strong>&nbsp; NCT03794297<\/p>","protected":false},"excerpt":{"rendered":"<p>Study Objective:&nbsp; This phase II trial investigates the efficacy and safety of dabrafenib and trametinib treatment in patients with Erdheim Chester disease that have BRAF V600 gene mutations. Sponsor:&nbsp; National [&hellip;]<\/p>\n","protected":false},"featured_media":0,"parent":0,"menu_order":0,"template":"","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","cybocfi_hide_featured_image":"","wds_primary_study_trials_cat":0,"_links_to":"","_links_to_target":""},"study_trials_cat":[32],"class_list":["post-4413","study_trials","type-study_trials","status-publish","hentry","study_trials_cat-drug-trial"],"_links":{"self":[{"href":"https:\/\/www.erdheim-chester.org\/hi\/wp-json\/wp\/v2\/study_trials\/4413","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.erdheim-chester.org\/hi\/wp-json\/wp\/v2\/study_trials"}],"about":[{"href":"https:\/\/www.erdheim-chester.org\/hi\/wp-json\/wp\/v2\/types\/study_trials"}],"wp:attachment":[{"href":"https:\/\/www.erdheim-chester.org\/hi\/wp-json\/wp\/v2\/media?parent=4413"}],"wp:term":[{"taxonomy":"study_trials_cat","embeddable":true,"href":"https:\/\/www.erdheim-chester.org\/hi\/wp-json\/wp\/v2\/study_trials_cat?post=4413"}],"curies":[{"name":"\u0921\u092c\u094d\u0932\u094d\u092f\u0942\u092a\u0940","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}